ライフサイエンスコーパス: trachoma

1 , diabetic retinopathy, night blindness, and trachoma.

2 ously named limbal corneal pits as a sign of trachoma.

3 reported a measure of the effect of WASH on trachoma.

4 pathogen and the etiologic agent of blinding trachoma.

5 g chlamydial infection and clinical signs of trachoma.

6 the prevention, diagnosis, and treatment of trachoma.

7 rchestrating the proinflammatory response in trachoma.

8 was used to look for associations of active trachoma.

9 mass treatment may be necessary to eliminate trachoma.

10 issue remodeling and recurrent trichiasis in trachoma.

11 limited data on humoral immune responses in trachoma.

12 utions in its strategy to eliminate blinding trachoma.

13 of sexually transmitted disease and blinding trachoma.

14 Subjects were examined for signs of trachoma.

15 scarring, particularly in the late stages of trachoma.

16 l the ocular strains of chlamydia that cause trachoma.

17 eatment has no added benefit on reduction of trachoma.

18 tion of the clinical disease signs of active trachoma.

19 oap (4.5;1.8-11.3) had association to active trachoma.

20 mydia trachomatis, the causative organism of trachoma.

21 mass drug administration of azithromycin for trachoma.

22 o, with coadministration of azithromycin for trachoma.

23 for meeting elimination criteria of blinding trachoma.

24 as the causative agent of the eye infection trachoma.

25 nsmitted infections and the blinding disease trachoma.

26 ndicator of decreased transmission of ocular trachoma.

27 region with the highest prevalence of active trachoma.

28 bout the epidemiology and pathophysiology of trachoma.

29 me-wide association study (GWAS) of scarring trachoma (1090 cases, 1531 controls) that identified 27

30 to 1,690), onchocerciasis (5,577 to 2,871), trachoma (506 to 159), and leprosy (36 to 26).

31 trauma (11.8%), refractive error (11.4%) and trachoma (7.6%).

32 erial conjunctival infections in cicatricial trachoma, a conjunctival swabbing of adults in rural Eth

33 ction with Chlamydia trachomatis can lead to trachoma, a leading infectious cause of blindness.

34 used to assess the prevalence of infectious trachoma after community-wide antibiotic treatments coul

35 prevalence and associated factors of active trachoma among children aged 1-9 years.

36 The prevalence of active trachoma among rural pre-school children in Wadla distri

37 ss the prevalence and associations of active trachoma among rural preschool children in Wadla distric

38 The prevalence of active trachoma among rural preschool children in Wadla distric

39 Trachoma, an infectious disease of the conjunctiva cause

40 Seventy-one communities with trachoma and annual azithromycin coverage data were enro

41 It is the etiological agent of blinding trachoma and bacterial sexually transmitted diseases, in

42 isease and infection rates in the long term, trachoma and C. trachomatis infection were not eliminate

43 ness of cataract, glaucoma, night blindness, trachoma and diabetic retinopathy (p<0.05).

44 namely cataract, glaucoma, night blindness, trachoma and diabetic retinopathy in Nepal.

45 reas awareness of cataract, night blindness, trachoma and diabetic retinopathy was associated with ag

46 on (URR) (N = 840) underwent examination for trachoma and had blood collected for detection of antibo

47 to report the effects of WASH conditions on trachoma and identify research gaps.

48 w census and survey of current residents for trachoma and infection was conducted.

49 The rates of active trachoma and infection with C. trachomatis were determin

50 We determined the prevalence of trachoma and infection with Chlamydia trachomatis in com

51 ith azithromycin after a baseline survey for trachoma and infection.

52 entative strains of C. trachomatis from both trachoma and lymphogranuloma venereum (LGV) biovars from

53 hlamydia trachomatis, the causative agent of trachoma and many sexually transmitted diseases , leads

54 ival fibroblasts from patients with scarring trachoma and matching control individuals, and compared

55 Similarly, awareness of cataract, glaucoma, trachoma and night blindness was associated with female

56 baseline, 6 months, and 1 year for clinical trachoma and ocular C trachomatis infection.

57 en years in all households were examined for trachoma and ocular infection with C. trachomatis at bas

58 after mass antibiotic treatment could reduce trachoma and ocular infection with Chlamydia trachomatis

59 shared services-for example, for eye health (trachoma and onchocerciasis), ulcer care (leprosy), or r

60 th a marker and risk factor for inflammatory trachoma and severe trachomatous disease.

61 of research into developing vaccines against trachoma and sexually transmitted chlamydial infections.

62 homatis is the etiological agent of blinding trachoma and sexually transmitted disease.

63 ns of individuals globally, causing blinding trachoma and sexually transmitted disease.

64 hlamydia trachomatis, the causative agent of trachoma and sexually transmitted diseases, multiply in

65 e severe health problems, including blinding trachoma and sexually transmitted diseases.

66 hlamydia trachomatis is responsible for both trachoma and sexually transmitted infections, causing su

67 Chlamydia trachomatis causes both trachoma and sexually transmitted infections.

68 urgery were evaluated for presence of active trachoma and signs of cicatricial outcomes of trachoma,

69 All available children were examined for trachoma and swabs were collected for microbiologic cult

70 ions, and to assess the prevalence of active trachoma and unclean faces.

71 This finding is essentially pathognomic of trachoma and was welcomed as a sign that could reliably

72 ing subjects in the community who had active trachoma and were also heterozygous for the H-RISK.

73 4 to 15 years with clinical signs of active trachoma and/or infection with C. trachomatis.

74 children were examined for clinical signs of trachoma, and conjunctival swabs were collected for C. t

75 n ages 5 years and younger was evaluated for trachoma, and determination of Chlamydia trachomatis inf

76 Children were examined for clinical trachoma, and swab samples were taken for determination

77 The children were examined for signs of trachoma, and swabs were collected for bacteriological c

78 macular degeneration, diabetic retinopathy, trachoma, and uncorrected refractive error in 1990-2010

79 sts that ocular tropism and association with trachoma are functionally associated with some sequence

80 Data on the impact of WASH on trachoma are needed to support policy and program recomm

81 echanisms underlying progressive fibrosis in trachoma are unknown.

82 To eliminate trachoma as a public health problem, the WHO recommends

83 ization's strategy for global elimination of trachoma as a public health problem.

84 cess to sanitation was associated with lower trachoma as measured by the presence of trachomatous inf

85 RCT examined treatment of river blindness or trachoma as part of an intervention to target 2 or more

86 uch estimates are particularly important for trachoma because of the absence of a true "gold standard

87 t the ocular strains of chlamydia that cause trachoma, but may also be efficacious against respirator

88 ategy in order to eliminate blindness due to trachoma by 2020 through "surgery," "antibiotics," "faci

89 World Health Organization seeks to eliminate trachoma by 2020, countries are beginning to control the

90 6 children were screened for signs of active trachoma by using cluster-sampling technique.

91 mination goals (for lymphatic filariasis and trachoma) by 2020 or 2021 and their control goals soon t

92 esults show that substantial falls in active trachoma can occur where SAFE is implemented, and that g

93 ntestinal helminthiasis, schistosomiasis and trachoma) can be used to define eligible target populati

94 Trachoma, caused by repeated infections with ocular Chla

95 Trachoma, caused by the obligate intracellular organism

96 s phylogeny show that there is only a single trachoma-causing clade, which is distinct from the linea

97 a, diabetic retinopathy, night blindness and trachoma compared to those from a semi-urban community a

98 In a region of Ethiopia with endemic trachoma, conjunctival bacterial growth was more common

99 They were evaluated for clinical trachoma, conjunctival swabs were tested for chlamydial

100 As mass azithromycin distribution for trachoma continues and is considered for other indicatio

101 at the mass distribution of azithromycin for trachoma control (MDA) may increase circulation of macro

102 the assay in the planning and monitoring of trachoma control activities.

103 thromycin mass drug administration (MDA) for trachoma control has been confirmed by a recent large ra

104 Epidemiological models of trachoma control indicate that a vaccine with this degre

105 Mass administration of azithromycin for trachoma control led to a sustained reduction in all-cau

106 strategy in the Amhara Region, Ethiopia, the Trachoma Control Program distributed over 124 million do

107 A trachoma control programme was started in southern Sudan

108 hromycin distribution is a core component of trachoma control programmes and could reduce mortality i

109 Although trachoma control programs frequently use the World Healt

110 Trachoma control programs to reduce risk of scarring are

111 standardized approaches to measuring WASH in trachoma control programs.

112 ated and may have important implications for trachoma control strategies and prevention of blindness.

113 onal research is needed to determine optimal trachoma control strategies, including evaluation of the

114 ation recommends mass treatment as part of a trachoma control strategy.

115 ive to disease-specific schemes in cataract, trachoma control, infectious corneal ulceration, cytomeg

116 rial of mass azithromycin administration for trachoma control.

117 Trachoma-control programmes distribute oral azithromycin

118 en, who are a core group for transmission of trachoma, could eventually eliminate infection from the

119 trial of mass azithromycin distributions for trachoma created a convenient experiment to test the hyp

120 3 years of mass treatment, the prevalence of trachoma decreased in a linear fashion with number of ye

121 h low (10%-20%) initial prevalence of active trachoma did not have MDA stopped before 3 annual rounds

122 Trachoma disappeared from high income countries through

123 reatment to halt the progression of scarring trachoma due to an incomplete understanding of disease p

124 tudies have focused on immune mechanisms for trachoma during chronic stages of infection, less resear

125 d to severe chronic complications, including trachoma, ectopic pregnancy, and infertility.

126 reported a measure of the effect of WASH on trachoma, either active disease indicated by observed si

127 trachomatis, after antibiotic treatment for trachoma, either through transfer of secretions from nos

128 asis (TT) surgery are undermining the global trachoma elimination effort.

129 rnerstone of the World Health Organization's trachoma elimination program.

130 lar disease is currently used for evaluating trachoma elimination programs, but serological surveilla

131 ping, impact monitoring, and surveillance in trachoma elimination programs.

132 antibiotic MDA is not currently required for trachoma elimination purposes in these settings.

133 e findings support the importance of WASH in trachoma elimination strategies and the need for the dev

134 lp inform rational design of diagnostics for trachoma elimination, we outline a nonparametric multile

135 Mass treatment with azithromycin for trachoma endemic communities typically excludes infants

136 hildren with clinical signs of trachoma in a trachoma endemic region of northern Australia.

137 A cross-sectional survey was conducted in a trachoma endemic village in Tanzania.

138 In a trachoma-endemic area, mass distribution of oral azithro

139 tional study was performed in two previously trachoma-endemic areas of The Gambia.

140 h is critical to understanding serostatus in trachoma-endemic areas.

141 a--frequent causes of childhood mortality in trachoma-endemic areas.

142 be achieved with the SAFE strategy in other trachoma-endemic areas.

143 apply it to 2 longitudinal cohort studies of trachoma-endemic communities in Tanzania (2000-2002) and

144 c distribution of antibiotics to children in trachoma-endemic communities reduces chlamydial infectio

145 C. trachomatis infection in individuals from trachoma-endemic communities with or without end-stage t

146 zation recommends annual treatment of entire trachoma-endemic communities, although children typicall

147 on in their families after mass treatment in trachoma-endemic communities.

148 al survey of children living in an untreated trachoma-endemic community in Tanzania.

149 In this trachoma-endemic community, incident scarring was high,

150 Country programs in trachoma-endemic regions must realistically expect that

151 ects without disease, all of whom resided in trachoma-endemic regions of Nepal.

152 or in 664 children aged 1-9 years in remote, trachoma-endemic villages in Tanzania.

153 rachomatis infection of Tanzanians living in trachoma-endemic villages were examined to determine pos

154 ular C. trachomatis infection in children in trachoma-endemic villages.

155 arrhea, soil-transmitted helminth infection, trachoma, environmental enteric dysfunction, and growth

156 play an important role in the progression of trachoma, especially with regard to the development of c

157 We further demonstrate that scarring trachoma fibroblasts can promote Akt phosphorylation in

158 We show that scarring trachoma fibroblasts substantially differ from control c

159 stinctive molecular fingerprint for scarring trachoma fibroblasts, and identified IL-6- as a potentia

160 s significantly associated with inflammatory trachoma + follicular trachoma (OR, 3.76; 95% CI, 1.70-8

161 Individuals (n = 3186) were graded for trachoma followed by conjunctival sampling to detect chl

162 comed as a sign that could reliably diagnose trachoma from other external diseases.

163 To determine the prevalence of trachoma from surveys among 4 districts in Nepal (Dailek

164 in places where the prevalence of follicular trachoma (FT) is greater than 10%.

165 ronmental improvement) to eliminate blinding trachoma globally by the year 2020.

166 ity, have no ocular condition that prevented trachoma grading or ocular specimen collection, and have

167 were graded according to the WHO simplified trachoma grading system.

168 Clinical trachoma grading was performed, and conjunctival samples

169 His diagnostic acumen in the field of trachoma has justly stood the test of time.

170 omatis infection were not eliminated in this trachoma hyperendemic village 3.5 years after two rounds

171 B*11 may offer protection from trichiasis in trachoma hyperendemic villages.

172 Twelve trachoma-hyperendemic communities were treated with 3 an

173 th Organization recommends mass treatment of trachoma-hyperendemic communities, but there are scant e

174 Among individuals with trachoma, IgG antibody responses to CPAF are likely to b

175 d from young children with clinical signs of trachoma in a trachoma endemic region of northern Austra

176 en are the sentinel markers of infection and trachoma in communities, so data are presented specifica

177 f fly control and antibiotic distribution on trachoma in hyperendemic communities.

178 tting was 4 districts previously endemic for trachoma in Nepal.

179 e that is safe and efficacious in preventing trachoma in nonhuman primates, a model with excellent pr

180 This strategy has successfully eliminated trachoma in several countries and global efforts are und

181 ificity of laboratory and clinical tests for trachoma in the absence of a gold standard.

182 prevalence and associated factors of active trachoma in the study community after the intervention w

183 tility and preventable infectious blindness (trachoma) in the world.

184 rachoma and signs of cicatricial outcomes of trachoma, including number of trichiatic lashes, epilati

185 expression in the conjunctiva during active trachoma infection.

186 eyes, a relevant experimental model of human trachoma infection.

187 International Trachoma Initiative, Murdoch Children's Research Institu

188 Trachoma is a conjunctiva scarring disease, which is the

189 Trachoma is a contagious infection of the eye.

190 Trachoma is a neglected eye disease and an important cau

191 Trachoma is a poorly understood immunofibrogenic disease

192 Blinding trachoma is an ancient neglected tropical disease caused

193 Trachoma is caused by Chlamydia trachomatis (Ct).

194 The pathophysiology of blinding trachoma is driven by multiple episodes of reinfection o

195 ival swab samples from a population in which trachoma is endemic in Guinea Bissau, we evaluated the s

196 In an African community where trachoma is endemic, we have previously identified an IL

197 sessed in a treatment-naive population where trachoma is hyperendemic.

198 Trachoma is initiated during childhood following repeate

199 The immunological basis of scarring trachoma is not well understood.

200 at the immunofibrogenic response in scarring trachoma is partly stimulated by nonchlamydial bacterial

201 This indicates that Trachoma is still a public health problem in the distric

202 Trachoma is targeted for elimination by 2020.

203 Trachoma is the leading infectious cause of blindness wo

204 Trachoma is the leading infectious cause of blindness.

205 Trachoma is the most common infectious cause of blindnes

206 Trachoma is the most common infectious cause of blindnes

207 Trachoma is the world's leading cause of infectious blin

208 Trachoma isolates and the sexually transmitted serotypes

209 The Australian trachoma isolates appear to be recombinants with UGT C.

210 In regions with low levels of endemic trachoma, it is possible that much of the TF that is obs

211 two lineages that fall outside the classical trachoma lineage, instead being placed within UGT clades

212 ydia trachomatis nMOMP in a nonhuman primate trachoma model.

213 Trachoma occurs in resource-poor areas with inadequate h

214 Eyes were graded for active trachoma; ocular swabs were taken to test for C. trachom

215 ment will be needed to reach a prevalence of trachoma of <5%.

216 and control of 5 NTDs-lymphatic filariasis, trachoma, onchocerciasis, schistosomiasis, and soil-tran

217 transmitted helminths, lymphatic filariasis, trachoma, onchocerciasis, visceral leishmaniasis, and ga

218 In comparison, trachoma, onchocerciasis, vitamin A deficiency, and refr

219 At 5 years, there were no differences in trachoma or infection rates, when comparing new resident

220 homatis pathobiotypes associated with either trachoma or sexually transmitted diseases, but differenc

221 ated with inflammatory trachoma + follicular trachoma (OR, 3.76; 95% CI, 1.70-8.33; P=0.04).

222 ecent reports have shown that infection with trachoma organisms lacking the cryptic chlamydial plasmi

223 of effect for a comparable WASH exposure and trachoma outcome, we conducted a random-effects meta-ana

224 r awareness of cataract, night blindness and trachoma (p<0.05).

225 s of cataract, glaucoma, night blindness and trachoma (p<0.05).

226 a, diabetic retinopathy, night blindness and trachoma (p<0.05).

227 al virulence factor and its contributions to trachoma pathogenesis.

228 in nine Ethiopian villages with hyperendemic trachoma, persons 40 years of age or older with signs or

229 omiasis, soil-transmitted helminthiasis, and trachoma, possible synergies between existing disease-sp

230 Trachoma presents distinct clinical syndromes ranging fr

231 suggests that, for communities with baseline trachoma prevalence of 50% and annual treatment coverage

232 ldren aged 1-9 years within population-based trachoma prevalence surveys.

233 cin was provided in 4 of 8 communities where trachoma prevalence was >/=10%.

234 uartile range (IQR) (1.8%, 7.7%); the median trachoma prevalence was 9.4%, IQR (6.6%, 15%).

235 National trachoma programmes could benefit from identifying and a

236 ies to Ct antigens is potentially useful for trachoma programmes, but consideration should be given t

237 that azithromycin might remain effective for trachoma programmes, but evidence is scarce.

238 Trachoma programs have had remarkable success at reducin

239 The trachoma rate did not differ significantly in the interv

240 th C trachomatis in communities with average trachoma rates at 12% to 13% cannot be eliminated before

241 At 5 years, trachoma rates were still lower than baseline, ranging f

242 ion of children, could interrupt the natural trachoma reinfection cycle.

243 Despite this, trachoma remained hyperendemic in many districts and a c

244 Trachoma remains the leading infectious cause of blindne

245 Trachoma remains the leading preventable infectious caus

246 Trachoma results from repeated episodes of conjunctival

247 ecommended antibiotic treatment strategy for trachoma's elimination as a public health problem, is ne

248 are workers, previously trained to undertake trachoma screening for one month, performed eye examinat

249 s are available for single isolates from the trachoma (serotype A) and sexually transmitted (serotype

250 achoma strains representative of the 3 major trachoma serotypes, using microarray-based comparative g

251 ere are three biovariants of C. trachomatis: trachoma (serotypes A-C) and two sexually transmitted pa

252 Chlamydia trachomatis isolates that cause trachoma, sexually transmitted genital tract infections

253 Cynomolgus macaques infected ocularly with a trachoma strain deficient for the 7.5-kb conserved plasm

254 Outside of ompA, trachoma strains differed primarily in a very small subs

255 isease outcome, we analyzed the genomes of 4 trachoma strains representative of the 3 major trachoma

256 late with differences in pathogenicity among trachoma strains.

257 , which studied females only, and the Family Trachoma Study (FTS), which compared persistently infect

258 ere are at risk of future complications from trachoma, supporting the conclusion that further antibio

259 bodies to chlamydia may be a useful tool for trachoma surveillance.

260 or sexually transmitted disease and blinding trachoma synthesize a highly conserved surface-exposed a

261 inst all possible combinations of follicular trachoma (TF) and inflammatory trachoma (TI).

262 WHO simplified criteria grades of follicular trachoma (TF) and intense trachomatous inflammation (TI)

263 ion-based surveillance survey for follicular trachoma (TF) and trachomatous trichiasis (TT) 2 years a

264 lence settings, clinically active follicular trachoma (TF) is often found in the absence of detectabl

265 Follicular trachoma (TF) was detected in 65 children (14%), C. trac

266 hromycin for the prevention and treatment of trachoma that assessed macrolide resistance, without res

267 are the etiologic agent of endemic blinding trachoma, the leading cause of bacterial sexually transm

268 Infection of the eye can result in trachoma, the leading cause of preventable blindness in

269 ydia trachomatis is the etiological agent of trachoma, the leading cause of preventable blindness.

270 Trachoma, the leading infectious cause of blindness, is

271 verify districts for elimination of blinding trachoma, the World Health Organization requires a popul

272 Trachoma, the world's leading cause of preventable blind

273 Overall, 30 (1.6%) individuals had active trachoma; the prevalence in children aged 1-9 years was

274 ively involved in late cicatricial stages of trachoma through the production of proinflammatory facto

275 of follicular trachoma (TF) and inflammatory trachoma (TI).

276 nization (WHO) simplified grading system for trachoma to monitor the clinical response after repeated

277 ndemic communities with or without end-stage trachoma (trichiasis) in The Gambia.

278 is study found no evidence of reemergence of trachoma up to 10 years after cessation of MDA in 4 dist

279 Selected children were examined for trachoma using 2.5x binocular loupe and graded based on

280 were interviewed for factors associated with trachoma using a structured questionnaire.

281 ogist examined all participants for signs of trachoma using WHO grading systems with additional asses

282 s were boosted i.m. with the live-attenuated trachoma vaccine and their peripheral T cell anamnestic

283 own that a plasmid-deficient live-attenuated trachoma vaccine delivered ocularly to macaques elicited

284 l pipeline and, in the case of an attenuated trachoma vaccine, are given to human subjects, it may be

285 rtant but unexpected role in live-attenuated trachoma vaccine-mediated protective immunity.

286 retinopathy was 29%, glaucoma was 21.3% and trachoma was 6.1%.

287 on of a single dose of oral azithromycin for trachoma was associated with increased circulation of ma

288 The prevalence of active trachoma was found 21.5% (95% CI: 17.8-25.1%).

289 However, his interest in trachoma was peripheral to his main professional work, w

290 Signs of trachoma were graded according to the WHO simplified tra

291 xaminations for the presence and severity of trachoma were performed.

292 nsmitted infections and the blinding disease trachoma, which affect hundreds of millions of people wo

293 al surveys, including clinical assessment of trachoma (WHO simplified system) and structured question

294 n (excluding pregnant women with no clinical trachoma, who were offered topical tetracycline).

295 We assessed indirect protection against trachoma with mass azithromycin distributions.

296 ion of IL10 in the conjunctiva during active trachoma, with the H-RISK generating relatively more IL1

297 ion of azithromycin (AZI) targeting yaws and trachoma, with the newly approved ivermectin, albendazol

298 or more inturned eyelashes) or inflammatory trachoma without trichiasis and control subjects without

299 l efforts are underway to eliminate blinding trachoma worldwide by 2020.

300 The Partnership for the Rapid Elimination of Trachoma-Ziada Trial was conducted from February 1, 2010